Filter by
Filter by
Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory lymphoma: A PTCOG and PCG Collaboration.
Symptomatic pneumonitis, a subacute toxicity, has an incidence of 17% to 24% (≥grade 2) even with IMRT. A total of 85 patients with r/r lymphoma (66% HL, 34%...
Selection of Mediastinal Lymphoma Patients for Proton Therapy Within the Proton Collaborative Group Registry: Concordance With the ILROG Guidelines.
This study reviewed 56 mediastinal lymphoma patients treated with proton therapy and reported that nearly all treated patients fit the International Lymphoma...